Literature DB >> 30543036

Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units.

Ophélie Maison1, Cléa Tardy2, Delphine Cabelguenne2, Stéphanie Parat2, Sophie Ducastelle3, Vincent Piriou4, Alain Lepape4, Laure Lalande2.   

Abstract

PURPOSE: Physicochemical incompatibility (PCI) between drugs infused together is frequent, but under-recognized. PCI can lead to drug inactivity, catheter occlusion, embolism or inflammatory reactions. The aims of this work were to identify most frequent and relevant drug incompatibilities and to review and develop strategies for their prevention.
METHOD: This was an observational prospective survey conducted between January and March 2015 in an intensive care unit (ICU) and in September 2014 in a hematology sterile unit (HSU). Drugs administered to patients were recorded and their compatibility assessed based on published compatibility data.
RESULTS: Drug incompatibilities accounted for 12% (23/189) and 17% (116/686) of drug pairs infused in the ICU and the HSU, respectively. Pantoprazole was the most frequent drug implied in PCI. Regarding drug classes, anti-infective agents and gastrointestinal drugs were the most frequently implied. Among the incompatible pairs, 78% and 61% implicated a drug with extreme pH in the ICU and HSU, respectively. The tools proposed to reduce the frequency of PCI included: compatibility cross-tables, labeling of drugs with extreme pH and optimized administration schedules.
CONCLUSIONS: Given the frequency and the potential for severe consequences of PCI, pharmacists have a role to play in raising awareness of nurses and practitioners, and proposing adequate tools and solutions to reduce their incidence.

Entities:  

Keywords:  Adverse drug events prevention; Drug incompatibilities; Intensive care unit; Intravenous therapy; Pharmacist

Mesh:

Substances:

Year:  2018        PMID: 30543036     DOI: 10.1007/s00228-018-2602-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Peripheral intravenous catheters in the care of oncology and haematology patients.

Authors:  Emily N Larsen; Gillian Ray-Barruel; Mari Takashima; Nicole Marsh; Christopher R Friese; Vineet Chopra; Evan Alexandrou; Claire M Rickard
Journal:  Aust J Cancer Nurs       Date:  2022-05

2.  Evaluation of Incompatible Coadministration of Continuous Intravenous Infusions in a Pediatric/Neonatal Intensive Care Unit.

Authors:  Chloé Häni; Priska Vonbach; Caroline Fonzo-Christe; Stefan Russmann; Vincenzo Cannizzaro; David F Niedrig
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Nov-Dec

Review 3.  Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review.

Authors:  Laura Négrier; Anthony Martin Mena; Gilles Lebuffe; Pascal Odou; Stéphanie Genay; Bertrand Décaudin
Journal:  Eur J Clin Pharmacol       Date:  2021-03-25       Impact factor: 2.953

4.  Quantitative assessment of required separator fluid volume in multi-infusion settings.

Authors:  Frank Doesburg; Daniek Middendorp; Willem Dieperink; Wouter Bult; Maarten W Nijsten; Daan J Touw
Journal:  J Vasc Access       Date:  2020-05-04       Impact factor: 2.283

Review 5.  Drug-drug interactions in polypharmacy patients: The impact of renal impairment.

Authors:  Bianca Papotti; Cinzia Marchi; Maria Pia Adorni; Francesco Potì
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-03-29

6.  Stability of vancomycin hydrochloride employed in antimicrobial seal solutions of central intravenous catheters.

Authors:  Daniele Porto Barros; Priscilla Sete de Carvalho Onofre; Fernando Luiz Affonso Fonseca; Paulo César Pires Rosa; Mavilde da Luz Gonçalves Pedreira; Maria Angélica Sorgini Peterlini
Journal:  Rev Lat Am Enfermagem       Date:  2022
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.